Phase III study of APF530 versus ondansetron with a neurokinin 1 antagonist plus corticosteroid in preventing highly emetogenic chemotherapy-induced nausea and vomiting: MAGIC trial.

被引：15

作者：

Schnadig, Ian D.

Agajanian, Richy

Dakhil, Shaker R.

Gabrail, Nashat Y.

Smith, Robert E.

Taylor, Charles W.

Wilks, Sharon

Cooper, William

Mosier, Michael

Payne, Yvette

Klepper, Michael

Vacirca, Jeffrey L.

机构：

[1] US Oncol Network, Compass Oncol, Tualatin, OR USA

[2] Oncol Inst Hope & Innovat, Whittier, CA USA

[3] Canc Ctr Kansas, Wichita, KS USA

[4] Gabrail Canc Ctr, Canton, OH USA

[5] South Carolina Oncol Associates, Columbia, SC USA

[6] Tulsa Canc Inst, Tulsa, OK USA

[7] Canc Care Ctr South Texas, San Antonio, TX USA

[8] TFS Int, Flemington, NJ USA

[9] EMB Stat Solut LLC, Overland Pk, KS USA

[10] Heron Therapeut Inc, San Diego, CA USA

[11] Drug Safety Navigator LLC, Durham, NC USA

[12] North Shore Hematol Oncol, East Setauket, NY USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 28期

关键词：

D O I：

10.1200/jco.2015.33.28_suppl.68

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：1

共 50 条

[1] Phase III MAGIC trial of APF530 v ondansetron (Ond) with fosaprepitant (Fos) plus dexamethasone (Dex) for highly emetogenic chemotherapy (HEC)-induced nausea and vomiting: analysis by age and gender.
Schwartzberg, Lee Steven
Gabrail, Nashat Y.
Hrom, John S.
Vogelzang, Nicholas J.
Mosier, Michael
Geller, Robert B.
Schnadig, Ian
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[2] Randomized phase III trial of APF530 versus palonosetron in the prevention of chemotherapy-induced nausea and vomiting in a subset of patients with breast cancer receiving moderately or highly emetogenic chemotherapy
Boccia, Ralph
O'Boyle, Erin
Cooper, William
BMC CANCER, 2016, 16
[3] Randomized phase III trial of APF530 versus palonosetron in the prevention of chemotherapy-induced nausea and vomiting in a subset of patients with breast cancer receiving moderately or highly emetogenic chemotherapy
Ralph Boccia
Erin O’Boyle
William Cooper
BMC Cancer, 16
[4] Effect of APF530 on health-related quality of life (QOL) and other chemotherapy-induced nausea and vomiting (CINV) end points: Phase III MAGIC trial.
Schnadig, Ian
Braun, Eduardo
Mosier, Michael
Geller, Robert B.
Schwartzberg, Lee Steven
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[5] Phase 3 trial of APF530 versus palonosetron (PALO) in preventing chemotherapy-induced nausea and vomiting (CINV): Efficacy in breast cancer patients (pts) receiving moderately (MEC) or highly (HEC) emetogenic chemotherapy.
Boccia, Ralph V.
Cooper, William
O'Boyle, Erin
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[6] APF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide-based highly emetogenic chemotherapy regimens: a post hoc subgroup analysis of the Phase III randomized MAGIC trial
Schnadig, Ian D.
Agajanian, Richy
Dakhil, Christopher
Gabrail, Nashat
Vacirca, Jeffrey
Taylor, Charles
Wilks, Sharon
Braun, Eduardo
Mosier, Michael C.
Geller, Robert B.
Schwartzberg, Lee
Vogelzang, Nicholas
CANCER MANAGEMENT AND RESEARCH, 2017, 9 : 179 - 187
[7] Phase III study of sustained release granisetron (APF530) compared to palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV)
Grous, J. J.
Riegel, E.
Gabrail, N.
Charu, V.
Arevalo-Araujo, R.
Yanagihara, R.
Nguyen, A.
Robertson, P.
Cooper, B.
O'Boyle, E.
Barr, J.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[8] A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy
Aapro, M. S.
Grunberg, S. M.
Manikhas, G. M.
Olivares, G.
Suarez, T.
Tjulandin, S. A.
Bertoli, L. F.
Yunus, F.
Morrica, B.
Lordick, F.
Macciocchi, A.
ANNALS OF ONCOLOGY, 2006, 17 (09) : 1441 - 1449
[9] Phase 3 comparison of APF530 versus ondansetron, each in a guideline-recommended 3-drug regimen for prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide (AC)-based highly emetogenic chemotherapy (HEC) regimens: A post hoc subgroup analysis of the MAGIC trial
Schnadig, I.
Agajanian, R.
Dakhil, S.
Taylor, C.
Wilks, S.
Cooper, W.
Mosier, M.
Payne, Y.
Klepper, M.
Vacirca, J.
CANCER RESEARCH, 2016, 76
[10] PHASE 3 STUDY COMPARING THE EFFICACY AND SAFETY OF SUSTAINED-RELEASE GRANISETRON (APF530) AND PALONOSETRON IN THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN CANCER PATIENTS RECEIVING MODERATELY OR HIGHLY EMETOGENIC CHEMOTHERAPY
Smith, Carrie
Gabrail, Nashat
ONCOLOGY NURSING FORUM, 2014, 41 (02) : E97 - E97

← 1 2 3 4 5 →